
Caribou Biosciences Investor Relations Material
Latest events

Q1 2025
8 May, 2025

Q4 2024
10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Caribou Biosciences Inc
Access all reports
Caribou Biosciences Inc. is a clinical-stage biopharmaceutical company at the forefront of genome editing technology. It focuses on developing genome-edited allogeneic cell therapies for the treatment of cancer and other devastating diseases. The company utilizes CRISPR-Cas9 technology to create precise, directed changes in the DNA of living cells, aiming to develop innovative therapies that can address unmet medical needs. Caribou's leading product candidates include allogeneic chimeric antigen receptor T (CAR-T) cell therapies for hematologic malignancies and solid tumors. This approach allows for the development of therapies that are not patient-specific but can be used as "off-the-shelf" treatments, potentially reducing time and cost compared to traditional autologous CAR-T therapies. The company is headquartered in Berkeley, CA, and its shares are listed on the NASDAQ.
Key slides for Caribou Biosciences Inc


Corporate Presentation
Caribou Biosciences Inc


Corporate Presentation
Caribou Biosciences Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CRBU
Country
🇺🇸 United States